tadalafil has been researched along with Myocardial Infarction in 16 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (43.75) | 29.6817 |
| 2010's | 6 (37.50) | 24.3611 |
| 2020's | 3 (18.75) | 2.80 |
| Authors | Studies |
|---|---|
| Das, A; Koka, S; Kukreja, RC; Samidurai, A; Wang, R; Xi, L | 1 |
| Blum, A; Konstantinovsky, A; Kridin, K; Kuchersky, N | 1 |
| Koka, S; Kukreja, RC; Xi, L | 1 |
| Frankenreiter, S; Friebe, A; Groneberg, D; Krieg, T; Kuret, A; Lukowski, R; Ruth, P | 1 |
| Adams, JL; Cook, MB; Finkle, WD; Frasco, MA; Fraumeni, JF; Greenland, S; Hoover, RN; Ridgeway, GK | 1 |
| Chau, VQ; Hoke, NN; Kukreja, RC; Salloum, FN | 1 |
| Abbate, A; Chau, VQ; Hoke, NN; Kukreja, RC; Ockaili, RA; Salloum, FN; Toldo, S; Varma, A | 1 |
| Ahmed, RP; Ashraf, M; Haider, HKh; Jiang, S; Lee, YJ; Ryon, M | 1 |
| Das, A; Durrant, DE; Hoke, NN; Kukreja, RC; Salloum, FN; Varma, A | 1 |
| Kloner, RA | 1 |
| Costigan, TM; Emmick, JT; Jackson, G; Kloner, RA; Warner, MR | 1 |
| Hall, TA; McGwin, G; Owsley, C; Vaphiades, MS | 1 |
| Chan, M; Costigan, TM; Hutter, AM; Jackson, G; Kloner, RA; Mittleman, MA; Vail, GM; Warner, MR | 1 |
| Kukreja, RC | 1 |
| Boshier, A; Harris, S; Hazell, L; Shakir, SA; Wilton, LV | 1 |
4 review(s) available for tadalafil and Myocardial Infarction
| Article | Year |
|---|---|
Treating diabetes with combination of phosphodiesterase 5 inhibitors and hydroxychloroquine-a possible prevention strategy for COVID-19?
Topics: Animals; COVID-19; COVID-19 Drug Treatment; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Hydroxychloroquine; Hyperglycemia; Insulin Resistance; Male; Mice; Myocardial Infarction; Phosphodiesterase 5 Inhibitors; Sildenafil Citrate; Tadalafil; Vardenafil Dihydrochloride | 2023 |
Cardiovascular effects of the 3 phosphodiesterase-5 inhibitors approved for the treatment of erectile dysfunction.
Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Adrenergic alpha-Antagonists; Arteriosclerosis; Blood Pressure; Carbolines; Contraindications; Coronary Disease; Cyclic GMP; Cyclic Nucleotide Phosphodiesterases, Type 5; Drug Interactions; Endothelium, Vascular; Erectile Dysfunction; Heart Rate; Humans; Hypotension; Imidazoles; Isosorbide Dinitrate; Male; Molecular Structure; Myocardial Infarction; Nitric Oxide Donors; Nitroglycerin; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Piperazines; Purines; Randomized Controlled Trials as Topic; Sildenafil Citrate; Sulfones; Tadalafil; Triazines; Vardenafil Dihydrochloride; Vasodilation; Vasodilator Agents | 2004 |
Update on clinical trials of tadalafil demonstrates no increased risk of cardiovascular adverse events.
Topics: Adult; Aged; Aged, 80 and over; Carbolines; Cardiovascular Diseases; Erectile Dysfunction; Humans; Male; Middle Aged; Myocardial Infarction; Phosphodiesterase Inhibitors; Randomized Controlled Trials as Topic; Risk Factors; Tadalafil | 2004 |
Cardiovascular safety update of Tadalafil: retrospective analysis of data from placebo-controlled and open-label clinical trials of Tadalafil with as needed, three times-per-week or once-a-day dosing.
Topics: Aged; Carbolines; Clinical Trials as Topic; Comorbidity; Coronary Artery Disease; Diabetes Mellitus; Dose-Response Relationship, Drug; Drug Administration Schedule; Erectile Dysfunction; Humans; Hyperlipidemias; Hypertension; Male; Middle Aged; Myocardial Infarction; Phosphodiesterase Inhibitors; Retrospective Studies; Tadalafil | 2006 |
12 other study(ies) available for tadalafil and Myocardial Infarction
| Article | Year |
|---|---|
Improvement in Endothelial Function in Men Taking Phosphodiesterase Type 5 Inhibitors for Erectile Dysfunction.
Topics: C-Reactive Protein; Carbolines; Erectile Dysfunction; Humans; Male; Myocardial Infarction; Phosphodiesterase 5 Inhibitors; Pilot Projects; Tadalafil; Treatment Outcome | 2023 |
Chronic inhibition of phosphodiesterase 5 with tadalafil affords cardioprotection in a mouse model of metabolic syndrome: role of nitric oxide.
Topics: Animals; Cardiotonic Agents; Disease Models, Animal; Dyslipidemias; Heart; Insulin Resistance; Male; Metabolic Syndrome; Mice; Mice, Inbred C57BL; Myocardial Infarction; Myocardial Reperfusion Injury; Nitrates; Nitric Oxide; Nitrites; Phosphodiesterase 5 Inhibitors; Tadalafil; Ventricular Function, Left | 2020 |
Cardioprotection by ischemic postconditioning and cyclic guanosine monophosphate-elevating agents involves cardiomyocyte nitric oxide-sensitive guanylyl cyclase.
Topics: Animals; Benzoates; Cyclic GMP; Disease Models, Animal; Enzyme Activators; Female; Ischemic Postconditioning; Large-Conductance Calcium-Activated Potassium Channels; Male; Mice, Knockout; Myocardial Infarction; Myocardial Reperfusion Injury; Myocytes, Cardiac; Nitric Oxide; Phosphodiesterase 5 Inhibitors; Signal Transduction; Sildenafil Citrate; Soluble Guanylyl Cyclase; Tadalafil; Tetrazoles; Thiourea; Time Factors; Up-Regulation | 2018 |
Increased risk of non-fatal myocardial infarction following testosterone therapy prescription in men.
Topics: Age Factors; Aged; Carbolines; Humans; Male; Middle Aged; Myocardial Infarction; Phosphodiesterase 5 Inhibitors; Piperazines; Prescription Drugs; Purines; Risk; Sildenafil Citrate; Sulfones; Tadalafil; Testosterone | 2014 |
Tadalafil prevents acute heart failure with reduced ejection fraction in mice.
Topics: Animals; Apoptosis; Carbolines; Cardiomegaly; Cardiomyopathies; Coronary Vessels; Heart Failure; Male; Mice; Mice, Inbred ICR; Myocardial Infarction; Phosphodiesterase Inhibitors; Pulmonary Edema; Tadalafil; Ventricular Dysfunction, Left; Ventricular Function, Left; Ventricular Remodeling | 2014 |
Phosphodiesterase-5 inhibitor, tadalafil, protects against myocardial ischemia/reperfusion through protein-kinase g-dependent generation of hydrogen sulfide.
Topics: Animals; Carbolines; Cyclic GMP-Dependent Protein Kinases; Cystathionine beta-Synthase; Female; Hemodynamics; Hydrogen Sulfide; Male; Mice; Mice, Inbred C57BL; Mice, Inbred ICR; Myocardial Infarction; Myocardial Reperfusion Injury; Phosphodiesterase 5 Inhibitors; Phosphodiesterase Inhibitors; Tadalafil; Ventricular Remodeling | 2009 |
Phosphodiesterase inhibition with tadalafil provides longer and sustained protection of stem cells.
Topics: Animals; Carbolines; Cell Proliferation; Cell Survival; Cells, Cultured; Cyclic GMP; Cyclic GMP-Dependent Protein Kinases; Cyclic Nucleotide Phosphodiesterases, Type 5; Dose-Response Relationship, Drug; Graft Survival; Male; Mesenchymal Stem Cell Transplantation; Mesenchymal Stem Cells; Models, Animal; Myocardial Infarction; Neovascularization, Physiologic; Phosphodiesterase Inhibitors; Rats; Rats, Inbred F344; Tadalafil; Time Factors | 2010 |
Anti-inflammatory and cardioprotective effects of tadalafil in diabetic mice.
Topics: Animals; Apoptosis; Blood Glucose; Body Weight; Carbolines; Cyclic Nucleotide Phosphodiesterases, Type 5; Diabetes Mellitus, Experimental; Drug Administration Schedule; Fasting; Interleukin-1beta; Male; Mice; Mice, Knockout; Myocardial Infarction; Myocardial Reperfusion Injury; Myocytes, Cardiac; Necrosis; Obesity; Phosphodiesterase Inhibitors; Receptors, Leptin; Tadalafil; Triglycerides; Tumor Necrosis Factor-alpha | 2012 |
Viagra and Cialis for heart failure? Erectile dysfunction drugs may do what no others have done.
Topics: Autonomic Nervous System; Carbolines; Cardiovascular Agents; Heart Rate; Humans; Myocardial Infarction; Piperazines; Purines; Sildenafil Citrate; Sulfones; Tadalafil; Vasodilator Agents | 2012 |
Non-arteritic anterior ischaemic optic neuropathy and the treatment of erectile dysfunction.
Topics: Carbolines; Case-Control Studies; Erectile Dysfunction; Humans; Hypertension; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Optic Neuropathy, Ischemic; Phosphodiesterase Inhibitors; Piperazines; Purines; Retrospective Studies; Sildenafil Citrate; Sulfones; Tadalafil; Vasodilator Agents | 2006 |
Cardiovascular protection with sildenafil following chronic inhibition of nitric oxide synthase.
Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Animals; Antihypertensive Agents; Carbolines; Cardiomyopathies; Cardiovascular Agents; Cyclic Nucleotide Phosphodiesterases, Type 5; Disease Models, Animal; Doxorubicin; Endothelium, Vascular; Enzyme Inhibitors; Erectile Dysfunction; Heart Failure; Humans; Hypertension; Hypertension, Pulmonary; Imidazoles; Male; Myocardial Infarction; Myocardial Reperfusion Injury; NG-Nitroarginine Methyl Ester; Nitric Oxide; Phosphodiesterase Inhibitors; Piperazines; Purines; Sildenafil Citrate; Sulfones; Tadalafil; Triazines; Vardenafil Dihydrochloride; Vasodilator Agents; Ventricular Remodeling | 2007 |
An observational cohort study investigating the cardiovascular safety of tadalafil when prescribed in primary care in England: mortality due to ischaemic heart disease.
Topics: Aged; Carbolines; Cohort Studies; England; Erectile Dysfunction; Family Practice; Humans; Incidence; Male; Middle Aged; Myocardial Infarction; Myocardial Ischemia; Phosphodiesterase Inhibitors; Surveys and Questionnaires; Tadalafil | 2007 |